Searches for a “license agreement template” usually mean one of two different things: a blank fill-in-the-blanks form, or a real, finished example showing what a completed agreement actually looks like once every clause is drafted out. There is no single universal template that fits every deal — language varies by institution, counsel, technology, and negotiation — so a generic downloadable form is rarely useful for a real transaction. What is useful is seeing the structure filled in with realistic language. This guide does that: it follows the clause-by-clause structure explained in CASRAI’s License Agreement Structure guide and shows, clause by clause, what each one looks like once it has actually been drafted.
This is an illustrative composite example, not a real agreement. “Meridian State University” and “Aldergrove Diagnostics, Inc.” are fictional parties, and the invention, dollar figures, percentages, and dates below are illustrative parameters chosen to show what finished clause language looks like — they are not benchmarks, defaults, or recommendations for any real negotiation. For how real royalty rates and payment terms are actually set, see CASRAI’s royalty rate setting methodology guide. Nothing on this page is legal advice or a substitute for review by qualified institutional counsel or a technology transfer office (TTO) before use in an actual agreement.
The Illustrative Scenario
In this fictional example, Meridian State University (the “Licensor”) owns a patent-pending diagnostic technology developed with federal research funding, making the invention subject to the Bayh-Dole Act. Aldergrove Diagnostics, Inc. (the “Licensee”), a small in-vitro diagnostics company, wants an exclusive license to develop and commercialize an in-vitro diagnostic (IVD) product based on the technology. Before reaching this stage, Aldergrove would typically have completed a due diligence review of the technology and the university’s expectations — see CASRAI’s due diligence questionnaire for technology licensing for what that process usually covers.
Recitals and Definitions
The recitals set the factual background the rest of the agreement relies on. A sample recitals paragraph:
WHEREAS, Licensor is the owner of certain patent rights relating to [invention title], developed in the course of federally sponsored research and subject to 35 U.S.C. §§ 200-212 (the Bayh-Dole Act); and WHEREAS, Licensee desires to obtain, and Licensor is willing to grant, a license under such patent rights on the terms set forth below, NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties agree as follows:
The definitions section then pins down exactly what later clauses refer to. Sample definitions:
“Licensed Patents” means U.S. Patent Application No. [XX/XXX,XXX], entitled [invention title], and any patents issuing therefrom, together with all continuations, divisionals, reissues, and foreign counterparts.
“Licensed Products” means any product, the manufacture, use, or sale of which would, absent this Agreement, infringe a Valid Claim of the Licensed Patents.
“Net Sales” means gross revenue actually received by Licensee or its sublicensees from the sale of Licensed Products, less returns, credits, and standard deductions for freight, insurance, and sales taxes actually paid.
“Field of Use” means human in-vitro diagnostic applications only, excluding therapeutic and veterinary applications.
Grant of Rights
This is the operative clause — what scope of rights the Licensee actually receives. CASRAI’s structure guide discusses the exclusivity, field, and territory choices behind this clause in more depth; here is what a resulting clause might read like:
Subject to the rights retained by the United States Government under the Bayh-Dole Act, Licensor hereby grants to Licensee an exclusive, worldwide license under the Licensed Patents to make, have made, use, sell, offer for sale, and import Licensed Products solely within the Field of Use. Licensor retains a non-exclusive, non-transferable right to practice the Licensed Patents for its own internal research, teaching, and non-commercial scholarly purposes.
Sublicensing
Because the Licensee here is a small company that may partner with a larger distributor or manufacturer, the agreement addresses sublicensing directly:
Licensee may grant sublicenses within the Field of Use, provided that (a) Licensee provides Licensor with written notice and a copy of each sublicense agreement within thirty (30) days of execution, (b) each sublicense is consistent with the terms of this Agreement, and (c) Licensee pays Licensor twenty percent (20%) of all sublicense income received, in addition to royalties otherwise due on Net Sales by the sublicensee.
Consideration and Payment Structure
The payment terms below are illustrative figures only, chosen to show what a filled-in payment schedule looks like — not typical or recommended values. Actual royalty rates and fees vary substantially by field, deal stage, and institution; CASRAI’s royalty rate setting methodology guide discusses how real rates are set, noting that reported academic licensing royalty rates commonly fall in roughly the 1%-10% of net sales range, with early-stage academic technology more typically toward 2%-6%, though no single authoritative figure applies across deals.
- Execution fee: $25,000, due within thirty (30) days of the Effective Date.
- Running royalty: 3% of Net Sales, paid quarterly.
- Minimum annual royalty: $10,000 per year, beginning in year three, creditable against running royalties owed for that year.
- Milestone payments: $50,000 upon first regulatory clearance of a Licensed Product; $100,000 upon first commercial sale.
- Sublicense income share: 20%, as described above.
- Patent costs: Licensee reimburses Licensor’s reasonable documented patent prosecution and maintenance costs.
Diligence Obligations
Because an exclusive license takes the technology off the market for anyone else, diligence obligations give the Licensor a way to confirm the Licensee is actually developing it. A sample clause:
Licensee shall (a) deliver a written development and commercialization plan to Licensor within sixty (60) days of the Effective Date; (b) develop a working prototype of a Licensed Product within eighteen (18) months; (c) file for applicable regulatory clearance within thirty-six (36) months; and (d) provide Licensor with semiannual written progress reports. If Licensee fails to meet any milestone above and does not cure such failure within sixty (60) days of written notice, Licensor may, at its option, convert the license to non-exclusive or terminate this Agreement.
Reporting, Audit, and Patent Prosecution
Shorter operational clauses round out the ongoing relationship between the parties:
Licensee shall deliver quarterly sales reports detailing Net Sales and royalties due. Licensor may audit Licensee’s relevant financial records, no more than once annually, upon thirty (30) days’ written notice. Licensor shall control the preparation, filing, prosecution, and maintenance of the Licensed Patents, in consultation with Licensee, and Licensee shall reimburse Licensor’s associated costs as set forth above.
Representations, Indemnification, and Insurance
University licensors typically limit their representations narrowly — they generally will not warrant that the licensed technology is free of third-party patent rights (freedom-to-operate), consistent with the discussion in CASRAI’s structure guide. A sample representation and indemnification structure:
Licensor represents that it has the right to grant the license set forth herein. LICENSOR MAKES NO OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THIRD-PARTY RIGHTS. Licensee shall indemnify, defend, and hold harmless Licensor from and against any claims, damages, and liabilities arising from Licensee’s development, manufacture, use, or sale of Licensed Products, and shall maintain commercial general liability and product liability insurance with minimum limits of $2,000,000 per occurrence, naming Licensor as an additional insured.
Term and Termination
A sample term and termination clause:
This Agreement shall remain in effect until the expiration of the last-to-expire Licensed Patent, unless earlier terminated. Either party may terminate this Agreement upon a material breach by the other party that remains uncured sixty (60) days after written notice. Licensee may terminate this Agreement for convenience upon ninety (90) days’ written notice. Obligations to pay accrued royalties, confidentiality obligations, and indemnification obligations shall survive termination.
Boilerplate
Every agreement also includes standard “boilerplate” provisions — governing law, restrictions on assignment, notice procedures, and an integration clause stating the written agreement is the entire understanding between the parties. These provisions are not deal-specific in the way the clauses above are, so they are not drafted out in full here; see CASRAI’s License Agreement Structure guide for what each of these covers.
Frequently Asked Questions
What is the difference between a license agreement template and a signed license agreement?
A template (blank form) shows the structure with placeholder brackets; a signed agreement has every term — parties, field of use, royalty rates, milestones, and so on — negotiated and filled in. The worked example on this page shows what that filled-in language looks like, using fictional, illustrative terms.
Can a generic online contract template be used for a university technology license?
Generally no. University technology licenses involve institution-specific requirements (Bayh-Dole compliance, retained research-use rights, government rights notices, institutional royalty-sharing policies) that a generic commercial contract template will not address. Most technology transfer offices draft from their own institution’s standard agreement, adapted per deal.
Who actually drafts the license agreement — the university or the company?
Typically the university’s technology transfer office or legal counsel provides the first draft, since the university owns the underlying intellectual property, and the company’s counsel then negotiates and redlines it. The balance of drafting can vary by institution and deal.
Is a license agreement example like this one legally binding?
No. This page is an illustrative, fictional composite meant to show what finished clause language looks like. It is not a binding agreement, is not legal advice, and should not be copied into an actual contract without review by qualified institutional counsel.
Where can I get an institution’s actual license agreement template?
Most technology transfer offices do not publish a public blank template, because license terms are negotiated individually for each deal rather than filled into one standard form. The best starting point is your own institution’s TTO or legal office; the Association of University Technology Managers (AUTM) is also a professional resource for licensing practice more broadly. The language on this page is illustrative only and is not a substitute for your institution’s own agreement paper.
For more on how each clause above is structured and negotiated, see CASRAI’s License Agreement Structure guide. Related reading: Non-Disclosure Agreements in Research Technology Transfer, Royalty Rate Setting Methodology, and the Tech Transfer pillar page.
